Ting-Yuan Tu,
Assistant Professor, Department of Biomedical Engineering,
National Cheng Kung University
Ting-Yuan (TY) TU is currently an Assistant Professor at Department of Biomedical Engineering at National Cheng Kung University (NCKU) in Taiwan. In collaboration with Singapore-MIT Alliance for Research and Technology Centre (SMART), he received his Ph.D. in Mechanobiology from National University of Singapore in 2015, in Singapore. Prior to joining NCKU, he was an Application Scientist at Clearbridge Biomedics, in which his role was focused on developing downstream assays for analysis of circulating tumor cells (CTCs) isolated from patients’ peripheral blood. In addition to studies on CTCs, another aspect of his current research interest lies in the development of better biomimetic tumor microenvironment for cancer drug discovery, such as in vitro tumor models and 3D tumor invasive co-culture microfluidic platforms.
The Next Generation Non-Invasive “Liquid Biopsy” for Cancer Management
Thursday, 30 November 2017 at 12:00
Add to Calendar ▼2017-11-30 12:00:002017-11-30 13:00:00Europe/LondonThe Next Generation Non-Invasive “Liquid Biopsy” for Cancer ManagementNext Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
Cancer accounts for millions of deaths worldwide each year, where metastases are responsible for 90% of cancer related deaths for most patients. Circulating tumor cells (CTCs) are sought to play a critical role in the metastatic process. In the recent decade, CTCs as a liquid biopsy material offers a simple and less invasive means to complement the current standard of multiple tissue biopsies or when biopsy material is absent or inadequate. Besides, CTCs provide information on the metastatic aggressiveness and molecular insights of the primary tumor or foreboding metastatic lesion. In this talk, I will review the development of analyses of CTCs. (1) The methodologies used for enrichment of CTCs and (2) clinical applications of enriched CTCs will be presented. I will demonstrate a label free and automated CTC enrichment system, the ClearCell® FX, leveraging an elegant microfluidic technology to offer a new perspective in clinical cancer diagnostics. Consistent and reproducible recovery of CTCs from prostate, breast and lung cancer will be demonstrated. Ultra-high purity, molecular analyses and other applications on CTCs will also be reported.
Add to Calendar ▼2017-11-30 00:00:002017-11-30 00:00:00Europe/LondonNext Generation Sequencing in the Clinic Asia Summit 2017Next Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-11-30 12:00:002017-11-30 13:00:00Europe/LondonThe Next Generation Non-Invasive “Liquid Biopsy” for Cancer ManagementNext Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
